What is Smart Immune?
Smart Immune, established in Paris, France, in 2017 by Marina Cavazzana, MD, PhD, Isabelle André, PhD, and Karine Rossignol, PharmD, is a biotechnology company focused on advancing Allogeneic T cell medicine. The company's proprietary ex vivo lymphoid niche technology underpins its ProTcell platform, designed to restore immune function in patients with life-threatening conditions such as high-risk leukemia and primary immunodeficiencies. This innovative approach aims to provide rapid, complete, and sustained immune recovery, offering new hope for patients battling severe diseases.
How much funding has Smart Immune raised?
Smart Immune has raised a total of $24.1M across 3 funding rounds:
Multiple Rounds
$24.1M
Private Equity (2023): $16.3M with participation from The European Innovation Council
Grant (2023): $2.7M led by The European Innovation Council
Grant (2023): $5M supported by Bill & Melinda Gates Foundation
Key Investors in Smart Immune
Bill & Melinda Gates Foundation
The Bill & Melinda Gates Foundation, a prominent philanthropic organization, focuses on global health and development initiatives, likely supporting Smart Immune's mission to combat life-threatening diseases through innovative medical research.
The European Innovation Council
The European Innovation Council, an entity supporting European innovation, provides crucial backing for promising technological advancements, aligning with Smart Immune's cutting-edge T cell therapy platform.
The European Innovation Council
As a key supporter of European technological progress, the European Innovation Council's investment in Smart Immune highlights the company's potential to drive significant advancements in the biotechnology sector.
What's next for Smart Immune?
With the recent influx of major strategic investment and substantial enterprise-level backing, Smart Immune is poised for significant advancements. The company's focus on developing its ProTcell platform, a thymus-empowered T cell therapy, indicates a strategic push towards scaling its operations and potentially initiating broader clinical trials. This capital infusion is critical for navigating the complex regulatory pathways and manufacturing requirements inherent in advanced cell therapy development, positioning Smart Immune to potentially transform treatment paradigms for hematological malignancies and infectious diseases.
See full Smart Immune company page
